Ioannis A Voutsadakis (I A Voutsadakis)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 50

Top Topics

Systematic Review

Prognostic Factors

Top Venues

Journal of clinical medicine

Current oncology (Toronto, Ont.)

Current issues in molecular biology

Pharmacological reports : PR

This page only lists publications with an associated author ORCID identifier.

Publications

Ioannis A Voutsadakis
Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer. Pharmacological reports : PR 76 (3) (2024)
Ioannis A Voutsadakis
Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer. Pharmacological reports : PR (2024)
Ioannis A Voutsadakis
Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies. Tissue barriers (2024)
Ioannis A Voutsadakis
Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer. Pharmacological reports : PR 76 (3) (2024)
Ioannis A Voutsadakis
Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. Journal of clinical medicine 12 (5) (2023)
Ioannis A Voutsadakis, Antonia Digklia
The Landscape and Therapeutic Targeting of BRCA1 , BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer. Current issues in molecular biology 45 (3) (2023)
Ioannis A Voutsadakis
Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. Journal of clinical medicine 12 (2) (2023)
Ioannis A Voutsadakis
Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes. Cancers 15 (10) (2023)
Ioannis A Voutsadakis
Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. Journal of clinical medicine 12 (2) (2023)
Ioannis A Voutsadakis
EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications. Current issues in molecular biology 45 (7) (2023)
Ioannis A Voutsadakis
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ioannis A Voutsadakis
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ioannis A Voutsadakis, Antonia Digklia
The Landscape and Therapeutic Targeting of BRCA1 , BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer. Current issues in molecular biology 45 (3) (2023)
Ioannis A Voutsadakis
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ioannis A Voutsadakis
Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. Journal of clinical medicine 12 (2) (2023)
Ioannis A Voutsadakis
Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. Journal of clinical medicine 12 (5) (2023)
Ioannis A Voutsadakis
Presentation, Molecular Characteristics, Treatment, and Outcomes of Colorectal Cancer in Patients Older than 80 Years Old. Medicina (Kaunas, Lithuania) 59 (9) (2023)
Ioannis A Voutsadakis
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current oncology (Toronto, Ont.) 30 (6) (2023)
Ioannis A Voutsadakis, Antonia Digklia
The Landscape and Therapeutic Targeting of BRCA1 , BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer. Current issues in molecular biology 45 (3) (2023)
Ioannis A Voutsadakis
Tight Junction Claudins and Occludin Are Differentially Regulated and Expressed in Genomically Defined Subsets of Colon Cancer. Current issues in molecular biology 45 (11) (2023)
Ioannis A Voutsadakis
Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. Current oncology (Toronto, Ont.) 29 (3) (2022)
Ioannis A Voutsadakis
The TSH/Thyroid Hormones Axis and Breast Cancer. Journal of clinical medicine 11 (3) (2022)
Christopher Rosso, Nicolas Fera, Nirosha J Murugan, Ioannis A Voutsadakis
Vitamin D Levels in Newly Diagnosed Breast Cancer Patients according to Tumor Sub-Types. Journal of dietary supplements (2022)
Ioannis A Voutsadakis
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers. Medical oncology (Northwood, London, England) 39 (5) (2022)
Ioannis A Voutsadakis
Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Medicina (Kaunas, Lithuania) 58 (10) (2022)
Ioannis A Voutsadakis
High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers. Journal of clinical medicine 11 (6) (2022)
Ioannis A Voutsadakis
The Genomic Environment of BRAF Mutated and BRAF / PIK3CA Double Mutated Colorectal Cancers. Journal of clinical medicine 11 (17) (2022)
Ioannis A Voutsadakis
Biomarkers of everolimus efficacy in breast cancer therapy. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (4) (2022)
Steven Davies, Ioannis A Voutsadakis
Adherence to adjuvant hormonal therapy in localised breast cancer. European journal of cancer care 31 (6) (2022)
Paul Mozarowski, Bhubendra Rasaiah, Melissa Reed, Alexis Lewis, Natalie Walde, Ioannis A Voutsadakis
Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy. Journal of clinical medicine 10 (4) (2021)
Stefania Kokkali, Athina Stravodimou, Jose Duran-Moreno, Nektarios I Koufopoulos, Ioannis A Voutsadakis, Antonia Digklia
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype. Expert review of anticancer therapy 21 (6) (2021)
Ioannis A Voutsadakis
PI3KCA Mutations in Uterine Cervix Carcinoma. Journal of clinical medicine 10 (2) (2021)
Ioannis A Voutsadakis
3q26 Amplifications in Cervical Squamous Carcinomas. Current oncology (Toronto, Ont.) 28 (4) (2021)
Ioannis A Voutsadakis
High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. Targeted oncology 15 (1) (2021)
Aaron Bertolo, Christopher Rosso, Ioannis A Voutsadakis
Breast Cancer in Patients 80 Years-Old and Older. European journal of breast health 16 (3) (2020)
Ioannis A Voutsadakis
8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy. Journal of clinical medicine 9 (10) (2020)
Ioannis A Voutsadakis
The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA. Cancer investigation 39 (1) (2020)
Ioannis A Voutsadakis
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets. Cancer management and research 12 (2020)
Ioannis A Voutsadakis
Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer. Molecular biology reports 47 (12) (2020)
AnnaLee Policicchio, Joey Mercier, Antonia Digklia, Ioannis A Voutsadakis
Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer. Journal of gastrointestinal cancer 50 (4) (2020)
Joey Mercier, Ioannis A Voutsadakis
Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer. Journal of gastrointestinal cancer 50 (3) (2020)
Ioannis A Voutsadakis
Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers. Molecular diagnosis & therapy 23 (6) (2020)
Vanessa Davies, Ioannis A Voutsadakis
Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry. Cancer investigation 38 (2) (2020)
Melissa Reed, Caitlyn Patrick, Travis Quevillon, Natalie Walde, Ioannis A Voutsadakis
Prediction of hospital admissions and grade 3-4 toxicities in cancer patients 70 years old and older receiving chemotherapy. European journal of cancer care 28 (6) (2019)
Brianna Croft, Melissa Reed, Caitlyn Patrick, Natalie Kovacevich, Ioannis A Voutsadakis
Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients. Journal of gastrointestinal cancer 50 (2) (2019)
Ioannis A Voutsadakis
Low-grade serous ovarian carcinoma: an evolution toward targeted therapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 30 (10) (2019)
Ioannis A Voutsadakis
Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications. Cellular oncology (Dordrecht) 41 (2) (2018)
Ioannis A Voutsadakis
HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 21 (5) (2018)
Ioannis A Voutsadakis
Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies. High-throughput 7 (4) (2018)
Ioannis A Voutsadakis
Clinical tools for chemotherapy toxicity prediction and survival in geriatric cancer patients. Journal of chemotherapy (Florence, Italy) 30 (5) (2018)